Charity criticises 'delay' to new Aberdeen Royal Infirmary unit
A cancer charity claims the opening of a planned new £2.5m specialist unit in Aberdeen has been delayed by at least a year.Swift Urological Responsive Evaluation (Sure) is expected to improve diagnosis times for people with symptoms of urological cancers.Ucan, which joined forces with Friends of Anchor to raise the money needed for the unit, said a change to where it would be located at Aberdeen Royal Infirmary had caused the delay.NHS Grampian said it needed to ensure the unit "fitted neatly" with other services.
Urological cancers include prostate, penis and testicular cancer, as well as kidney and bladder.
It had been intended the unit would be within the current urology department.But NHS Grampian said it was looking at setting it up in a different area of the hospital.Ucan chief executive Kenny Anderson, who has himself been treated for prostate cancer, has expressed "disappointment" at the change from the original plan.He said there were also ventilation concerns about the new location.The new unit could be open from May next year.
'Excellent facility'
NHS Grampian said it was crucial Sure was located in the right place.A spokesperson said: "We have further examined the initial proposal, and the original space earmarked for the Sure unit."We note some concerns about the area identified, however once refurbished it will provide an excellent facility for the location of the Sure unit."
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
BBC News
6 days ago
- BBC News
NHS Grampian: New chief executive to lead struggling health board
A new chief executive has been appointed by NHS Grampian, as the health board faces significant financial challenges. Laura Skaife-Knight, who is currently in a similar role at NHS Orkney, will take up the role when interim boss Dr Adam Coldwells retires in the Grampian is trying to implement £23m in savings amid a huge overspend. The health board had been escalated to stage four of NHS Scotland's National Performance Framework over concerns about its finances and governance. Ms Skaife-Knight has worked for the NHS for 20 years, including spending time in England. She said she was looking forward to joining NHS Grampian, and recognised the "immediate challenges ahead". The new chief executive will oversee a savings plan which includes services being stopped or reduced on public are also planned to a service providing spiritual, pastoral and religious care to patients, their relatives and carers and to Grampian has the highest forecasted financial overspend across NHS Scotland for the year ahead - despite it getting a Scottish government loan of more than £67m to tackle the health board's chairwoman, Alison Evison, welcomed Ms Skaife-Knight's said: "Laura joins us at a challenging time, but I know that as a leader and chief executive known for putting people first that she already recognises that NHS Grampian's talented staff and proven ability to deliver the very best care."
Sky News
19-06-2025
- Sky News
'Pioneering' new scanner used for brain tumour patients trialled in world-first
A "pioneering" new scanner derived from MRI technology could be used to track brain cancer spread and lead to improved treatment for patients, scientists have said. Researchers at the University of Aberdeen and NHS Grampian have been awarded £350,000 funding by the Scottish government to generate never-before-seen images of glioblastoma brain tumours. It is hoped the technology will improve treatment and quality of life for patients by investigating a new way to scan the tumours. Glioblastoma is the most common and aggressive type of brain tumour with more than 3,000 new patients in the UK diagnosed each year. The University of Aberdeen said half of all patients die within 15 months of diagnosis even after extensive surgery, radiotherapy and chemotherapy. Field cycling imaging (FCI) is a new and specialist type of low-field MRI scan pioneered in Aberdeen and has already been found to be effective in detecting tumours in breast tissue and brain damage in stroke patients. It is hoped it can now be used to help brain tumour patients. Full body MRI scanners were invented at the Scottish university 50 years ago, but the FCI scanner is the only one of its type used on patients anywhere in the world. The FCI derives from MRI but can work at low and ultra-low magnetic fields, which means it is capable of seeing how organs are affected by diseases in ways that were previously not possible. It can also vary the strength of the magnetic field during the patient's scan - acting like multiple scanners and extracting more information about the tissues. The tech can detect tumours without having to inject dye into the body, which can be associated with kidney damage and allergic reactions in some patients. Those involved in the project will scan glioblastoma patients undergoing chemotherapy after surgery and chemoradiotherapy. It is hoped the research will establish that, unlike conventional MRI scans, FCI can tell the difference between tumour growth and progression, and "pseudo-progression" which looks like tumour but is not cancerous tissue, which could improve care and quality of life. The new tech was described as "another example of the pioneering work coming out of the University of Aberdeen", by the charity Friends of ANCHOR. Professor Anne Kiltie, who is leading the study, said: "If we can detect true tumour progression early, we can swap the patient to a potentially more beneficial type of chemotherapy. "Also, being able to verify that a patient has pseudo-progression will prevent effective chemotherapy being stopped too early, because it was thought that the tumour has progressed, thus worsening prognosis. "Providing certainty will also reduce anxiety for both patients and relatives and improve the quality of life of patients. "Importantly, having a reliable method to identify progressive disease will allow development and more precise evaluation of emerging potential treatments. This is of particular importance as patients currently have a limited choice of treatments for combating their cancer. Scotland and beyond."
BBC News
19-06-2025
- BBC News
Aberdeen scanner study could improve brain tumour treatments
Scientists at the University of Aberdeen and NHS Grampian have secured funding to generate never-before-seen brain tumour images with the aim of improving of all glioblastoma patients die within 15 months of diagnosis even after surgery, radio and scans used to monitor a tumour's behaviour can be imprecise but it is hoped the Field Cycling Imaging (FCI) scanner - developed in Aberdeen - will give clinicians better £350,000 in support - from the Scottish government - will fund a trial which will be carried out on a group of 18 patients. MRI scanners were invented at the University of Aberdeen 50 years ago, but the new FCI scanner is the only one of its type used on patients anywhere in the can work at low and ultra-low magnetic fields which means it is capable of seeing how organs are affected by diseases in ways that were not previously can vary the strength of the magnetic field during the patient's scan - acting like multiple scanners and extracting more information about the new technology can detect tumours without having to inject dye into the body, which can be associated with kidney damage and allergic reactions in some team of doctors and scientists involved will scan glioblastoma patients undergoing chemotherapy after surgery and chemoradiotherapy. It is hoped the research will establish that, unlike conventional MRI scans, FCI can tell the difference between tumour growth and progression, and "pseudo-progression" which looks like a tumour but is not cancerous Anne Kiltie, chair in clinical oncology at the University of Aberdeen, who is leading the study, said: "We already have evidence that FCI is effective in detecting tumours in breast tissue and brain damage in stroke patients."Applying this exciting new technology to glioblastoma patients could give us a much more accurate and detailed picture of what is going on in their brain."If we can detect true tumour progression early, we can swap the patient to a potentially more beneficial type of chemotherapy."Providing certainty will also reduce anxiety for both patients and relatives and improve the quality of life of patients."Prof Kiltie's role at the university is fully funded by the charity Friends of ANCHOR through its Dream Big executive Sarah-Jane Hogg welcomed the "really promising" development and thanked donors and fundraisers for their support.
